SCHEMBL19917147

SCHEMBL19917147

Cc1nc(Cl)c(N)c(NC2CCCCC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.48
PDE4A P27815 3/20 0.44
CHRM3 P20309 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
CYP3A4 P08684 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CRHR1 P34998 2/20 0.42
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 2/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
NUDT1 P36639 1/20 0.39
GABBR2 O75899 2/20 0.39
GABBR1 Q9UBS5 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619235 0.98 PDE10A (0.49) PDE10APDE4ACHRM3PDE4BPDE4C
SCHEMBL12012377 0.84 PIK3CA (0.50) PDE10APDE4APDE4BPDE4CPDE4D
SCHEMBL21977311 0.81 PDE10A (0.44) PDE10APDE4ACHRM3PDE4BPDE4C
SCHEMBL19917177 0.80 KMT2A (0.52) PDE10APDE4ACHRM3PDE4BPDE4C
SCHEMBL2488800 0.79 CTSK (0.44)
SCHEMBL12012382 0.79 CTSK (0.44)
SCHEMBL2488799 0.79 CTSK (0.44)
SCHEMBL3120330 0.79 PDE10A (0.49) PDE10APDE4ACHRM3PDE4BPDE4C
SCHEMBL16714483 0.78 KMT2A (0.44) PDE10APDE4ACHRM3PDE4BPDE4C
SCHEMBL21057489 0.77 TLR7 (0.52) PDE10APDE4ACHRM3PDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
WO-2018038265-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND PDE7B, PDE3A, PDE7A PDE10A 12/4885PDE4A 10/4885CHRM3 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.